Daily Sepsis Research Analysis
Three impactful sepsis papers span therapeutic innovation, diagnostics, and prognosis. A preclinical study identifies Sigmoidin B as a novel EZH2 degrader that mitigates sepsis-associated encephalopathy, a meta-analysis confirms high diagnostic accuracy of presepsin across age groups, and a large ICU database study links the stress hyperglycemia ratio to mortality in sepsis-associated acute kidney injury.
Summary
Three impactful sepsis papers span therapeutic innovation, diagnostics, and prognosis. A preclinical study identifies Sigmoidin B as a novel EZH2 degrader that mitigates sepsis-associated encephalopathy, a meta-analysis confirms high diagnostic accuracy of presepsin across age groups, and a large ICU database study links the stress hyperglycemia ratio to mortality in sepsis-associated acute kidney injury.
Research Themes
- Epigenetic targeting for neuroinflammation in sepsis
- Age-spanning diagnostic biomarker validation for early sepsis recognition
- Glycemic stress metrics for prognostication in sepsis-associated organ dysfunction
Selected Articles
1. Sigmoidin B attenuates sepsis-associated encephalopathy through EZH2-AKT2-mediated regulation of microglial polarization.
Using macrophage-specific EZH2 knockout mice and in vivo/in vitro validation, the authors identify Sigmoidin B as a novel EZH2 degrader that shifts microglia toward an anti-inflammatory phenotype via the EZH2-AKT2 pathway. Sigmoidin B improved survival and cognitive outcomes in septic mice and outperformed the reference degrader MS177 in reducing inflammation.
Impact: This work introduces a first-in-class natural EZH2 degrader with demonstrated in vivo efficacy for sepsis-associated encephalopathy, advancing an epigenetic therapeutic strategy with mechanistic clarity.
Clinical Implications: Although preclinical, the data support EZH2 degradation as a therapeutic avenue for sepsis-associated encephalopathy and motivate translational development, including pharmacokinetics, safety, and blood-brain barrier penetration studies.
Key Findings
- Macrophage-specific EZH2 knockout increased survival, lowered TNF-α/CD86, and raised IL-10/CD206 in septic mice.
- Sigmoidin B was identified via virtual screening and showed strong binding to EZH2, acting as a degrader.
- In vivo validation demonstrated that Sigmoidin B ameliorated cognitive dysfunction and modulated microglial polarization through the EZH2-AKT2 pathway, outperforming MS177.
Methodological Strengths
- Use of macrophage-specific EZH2 knockout mice to establish causal relevance in sepsis pathobiology
- Convergent validation combining virtual screening, molecular dynamics, and in vivo/in vitro experiments
Limitations
- Preclinical study with unspecified sample sizes limits immediate clinical generalizability
- Computational binding and degrader activity require comprehensive pharmacokinetic/toxicity and off-target assessments
Future Directions: Define pharmacokinetics, safety, and BBB penetration; optimize dosing; test in larger animal models; and explore combination strategies with anti-inflammatory or neuroprotective agents.
PURPOSE: Enhancer of zeste homolog (EZH2) is a potential target in treatment of sepsis. The current study is aimed to screen a novel EZH2 degrader agent based on the Traditional Chinese Medicine Database YaTCM. This may provide an important clue for development of new drugs to treat sepsis-associated encephalopathy (SAE). METHODS: Macrophage-specific EZH2 knockout mice were used to observe the effects of EZH2 on the survival rate, levels of inflammatory cytokines, S100B, CD86, and CD206 in sepsis mice. Sigmoidin B was screened as the novel EZH2 degrader based on the structure of MS177 using large-scale virtual high-throughput screening. Molecular dynamics simulations and MMGBSA analysis were used to assess the stability and binding characteristics of Sigmoidin B. The protective effect of MS177 and the novel EZH2 degrader were verified using in vivo and vitro experiments. RESULTS: Macrophage-specific knockout of EZH2 had been shown to enhance the survival rate in mice with sepsis, reduce levels of CD86 and TNF-α, promote the expression of IL-10 and CD206, and mitigate the extent of brain injury. Sigmoidin B exhibited strong binding affinity to EZH2 and featured a flavonoid core structure along with an olefin side chain. Molecular validation experiments confirmed that Sigmoidin B could ameliorate cognitive dysfunction and modulate microglial polarization via the EZH2-AKT2 pathway. Notably, Sigmoidin B demonstrated superior efficacy compared to MS177 in alleviating inflammation. CONCLUSION: Natural compound Sigmoidin B was successfully screened and confirmed as a novel EZH2 degrader, which was a potential target for the development of new therapeutic for SAE.
2. Presepsin as a diagnostic biomarker for sepsis across neonates, children, and adults: A meta-analysis.
Across 47 studies (7,087 participants), presepsin achieved pooled sensitivity 0.84, specificity 0.86, and AUC 0.91, indicating strong diagnostic accuracy for sepsis. Performance was highest in neonates (AUC 0.96) and remained robust in children and adults, with heterogeneity sources identified and no significant publication bias.
Impact: Provides the most comprehensive age-stratified synthesis to date supporting presepsin as an early diagnostic biomarker for sepsis, with rigorous assessment of heterogeneity and study quality.
Clinical Implications: Presepsin can be integrated into early diagnostic pathways, particularly in neonates, to improve recognition of sepsis. Standardization of cutoffs and prospective multicenter validation are needed before widespread adoption.
Key Findings
- Pooled diagnostic performance: sensitivity 0.84, specificity 0.86, DOR 32.23, AUC 0.91.
- Highest accuracy in neonates (sensitivity 0.90, specificity 0.92, AUC 0.96), with robust performance in children and adults.
- Meta-regression identified publication year, region, specimen type, population, and diagnostic criteria as heterogeneity sources; no significant publication bias (p=0.33).
Methodological Strengths
- Comprehensive search across four databases with QUADAS-2 quality assessment
- Random-effects modeling with subgroup and meta-regression analyses and sensitivity testing
Limitations
- Substantial heterogeneity across studies and variability in presepsin cutoffs and diagnostic criteria
- Predominantly observational diagnostic studies; limited prospective standardization across centers
Future Directions: Prospective, multicenter studies to standardize cutoffs and assess integration with clinical scores and other biomarkers; evaluation of impact on time-to-antibiotics and patient outcomes.
Sepsis remains a leading global health challenge, with delayed recognition and limited diagnostic accuracy of current tools contributing to high morbidity and mortality. Conventional clinical scores (SOFA/qSOFA), standard biomarkers (CRP, PCT), and blood cultures suffer from delayed responsiveness, insufficient specificity, or slow turnaround, underscoring the urgent need for more reliable early diagnostic strategies. Presepsin, a soluble CD14 subtype generated during pathogen recognition by innate immune cells, has emerged as a promising biomarker with potential to reflect infection status earlier and more specifically than traditional markers. This systematic review and meta-analysis quantitatively evaluated the diagnostic accuracy of presepsin across diverse populations. PubMed, EMBASE, Web of Science, and Cochrane Library were searched for studies published between 2015 and 2025. Forty-seven studies involving 7,087 participants were included. Pooled sensitivity, specificity, diagnostic odds ratio (DOR), area under the curve (AUC), and likelihood ratios (PLR/NLR) with 95% confidence intervals (CI) were calculated using random-effects models. Heterogeneity was assessed with I² statistics, meta-regression, and subgroup analyses. Study quality was evaluated using QUADAS-2. Presepsin demonstrated excellent overall diagnostic performance: pooled sensitivity 0.84 (95% CI: 0.81-0.88), specificity 0.86 (95% CI: 0.80-0.90), DOR 32.23 (95% CI: 20.11-51.66), and AUC 0.91 (95% CI: 0.88-0.93). Subgroup analyses confirmed robust performance across settings and populations, with particularly high accuracy in neonates (sensitivity 0.90, specificity 0.92, AUC 0.96), followed by children (sensitivity 0.84, specificity 0.81, AUC 0.88, NLR 0.20) and adults (sensitivity 0.81, specificity 0.82, AUC 0.87). Meta-regression identified year of publication, geographic region, specimen type, population, and diagnostic criteria as key contributors to heterogeneity, but sensitivity analyses confirmed result stability. No significant publication bias was observed (p = 0.33). In conclusion, presepsin is a valuable and highly promising biomarker for sepsis diagnosis, showing favorable diagnostic accuracy across populations, with strongest utility in neonates. Its application in pediatric and adult patients warrants further validation through large, prospective, multi-center studies.
3. Association of stress hyperglycemia ratio with mortality in sepsis-associated acute kidney injury: a retrospective analysis of the MIMIC-IV database.
In 1,822 SA-AKI patients from MIMIC-IV, higher stress hyperglycemia ratio was associated with increased mortality, exhibiting a U-shaped relationship with a 30-day mortality inflection point at 0.67. Patients above the inflection had a 38.2% higher 30-day mortality risk (HR 1.382), supporting SHR as a pragmatic prognostic metric.
Impact: Leverages a large ICU database with advanced modeling to operationalize SHR as a risk metric in SA-AKI, highlighting a clinically actionable inflection point.
Clinical Implications: SHR can complement early risk stratification and may inform glucose management targets in SA-AKI. Prospective validation and interventional trials are needed to test SHR-guided glycemic strategies.
Key Findings
- In 1,822 SA-AKI patients, higher SHR was associated with increased in-hospital and 30-day mortality.
- Restricted cubic splines revealed a U-shaped relationship with a 30-day mortality inflection point at 0.67.
- Patients above the inflection had a 38.2% higher 30-day mortality risk (HR 1.382; 95% CI 1.198–1.593) after adjustment.
Methodological Strengths
- Large ICU cohort (MIMIC-IV) with multivariable Cox modeling and Kaplan–Meier analyses
- Use of restricted cubic spline modeling to characterize non-linear risk relationships
Limitations
- Retrospective single-database analysis with potential residual confounding and selection bias
- Limited granularity on glycemic management protocols and time-varying treatments
Future Directions: Prospective multicenter validation, definition of optimal SHR thresholds, and randomized trials testing SHR-guided glucose control in SA-AKI.
In recent years, the relationship between stress hyperglycemia ratio (SHR) and clinical outcomes in critically ill patients has garnered increasing attention. However, its role in predicting the prognosis of patients with sepsis-associated acute kidney injury (SA-AKI) remains unclear. This study aimed to clarify the relationship between SHR and all-cause mortality in patients with SA-AKI. We conducted a retrospective cohort study based on patient data from the Medical Information Mart for Intensive Care IV (MIMIC IV) database. Critically ill patients diagnosed with SA-AKI were stratified according to the quartiles of SHR. The primary outcome was all-cause mortality during hospitalization. Kaplan-Meier curve analysis was used to compare survival differences among the groups. A Cox proportional hazards model adjusted for confounding factors, was employed to investigate the relationship between SHR and mortality. A total of 1822 adult patients with sepsis-associated renal injury were included in the study. The average age was 68 years, 1059 (59.58%) were male. The patient's increased 30-day risk of death is associated with a higher SHR index, as indicated by the Kaplan-Meier curves (log-rank P < 0.001). Furthermore, Cox proportional-hazards regression analysis revealed that the risk of mortality was significantly higher in the highest quartile of the SHR index. Restricted cubic splines (RCS) analysis demonstrated U-shaped relationships between the SHR index and 30-day mortality, with inflection points at 0.67 for 30-day mortality. Compared to patients with SHR levels below these inflection points, those with higher levels had a 38.2% increased risk for 30-day all-cause mortality (hazard ratio [HR] 1.382; 95% confidence interval [CI] 1.198-1.593). In patients with sepsis-related acute kidney injury, the SHR index can be used as an effective indicator to assess severity and guide treatment. While elevated SHR portends an increased risk of death, inadequate acute glycemic regulation also merits attention. These findings underscore the importance of SHR-based management for the prognosis of critically ill patients with SA-AKI and highlight the need for further multicenter clinical studies to establish the optimal diagnostic threshold for SHR.